The role of farnesyltransferase inhibitors in lung cancer therapy

Grace K. Dy, Alex A. Adjei

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Protein farnesylation is required for the localization and function of several proteins pivotal to signal transduction pathways and cytoskeletal organization, including the Ras proteins. Ras proteins are constitutively activated in 30% of human tumors, including lung cancer tumors, as a consequence of mutations in ras genes. Farnesyltransferase inhibitors (FTIs) were thus designed to curtail the Ras-mediated aberrant signals that regulate cell proliferation, apoptosis, invasion, and angiogenesis. These processes are vital to the perpetuation of the malignant phenotype. However, current evidence suggests that the antitumor activity of FTIs is Ras-independent. This article reviews preclinical and clinical data pertinent to the use of FTIs in lung cancer.

Original languageEnglish (US)
Pages (from-to)57-62
Number of pages6
JournalClinical Lung Cancer
Issue number1
StatePublished - Jul 2002


  • Angiogenesis
  • BMS-214662
  • Lonafarnib
  • Ras
  • Tipifarnib

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research


Dive into the research topics of 'The role of farnesyltransferase inhibitors in lung cancer therapy'. Together they form a unique fingerprint.

Cite this